Posters

Early clinical outcomes of transepithelial corneal cross-linking with 0.2% solution of riboflavin in the treatment of corneal ectasia

Poster Details

First Author: M. Bikbov RUSSIAN FEDERATION

Co Author(s):    G. Bikbova   E. Usubov   N. Zaynullina   A. Khalimov           

Abstract Details

Purpose:

To conduct a comparative analysis of early clinical results of keratectasia treatment by Epi-on CXL with iontophoresis using 0.1% and 0.2% riboflavin solution.

Setting:

Ufa Eye Research Institute, Ufa, Russia

Methods:

43 patients (43 eyes) with primary ectasia underwent the treatment by Epi-on CXL with iontophoresis. In group 1 - 24 patients (24 eyes) - 0.1% solution of riboflavin, in group 2 - 19 patients (19 eyes) - 0,2% solution of riboflavin.Early follow-up period was 6 months. Corneal saturation with riboflavin was carried out by transepithelial method using iontophoresis with the initial 0.2 mA current with a gradual increase of power to 1.0 mA. Total saturation time - 15 minutes. Saturation of the cornea confirmed by yellow glow stroma and aqueous humor using biomicroscopy with blue cobalt filter.

Results:

During 6 months of a follow-up period uncorrected visual acuity in both groups remained stable in comparison with preoperative results and totalled 0.35±0.08 and 0.32±0.07. The indices of refractive power in group 1 before treatment averaged 46.7±0.41 D, in group 2 – 45.9±0.38 D. In both groups by 1st and 3d months the average value of refractive power hasn’t changed much compared to the preoperative one. By 6th month keratometry value decreased to 46.1±0.36 D (0.6 D, r≥0.07) in group 1 and 45.2±0.36 D (0.7D r≥0.06) in group 2. Corneal thickness in ectasia area in both groups decreased by 15-20 microns.

Conclusions:

Methods of epi-on CXL with iontophoresis and use of 0.1% and 0.2% riboflavin solutions are comparable with each other according to clinical and optometric parameters. The method reduces refractive power of the cornea and contributes to flattening of the cornea and stabilization of disease.

Financial Disclosure:

NONE